دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Association of Baseline Luminal Narrowing With Ileal Microbial Shifts and Gene Expression Programs and Subsequent Transmural Healing in Pediatric Crohn Disease
Allison D Ta, MD, Nicholas J Ollberding, PhD, Rebekah Karns, PhD, Yael Haberman, MD, PhD, Adina L Alazraki, MD, David Hercules, Robert Baldassano, MD, James Markowitz, MD, Melvin B Heyman, MD, Sandra Kim, MD, Barbara Kirschner, MD, Jason M Shapiro, MD, Joshua Noe, MD, Maria Oliva-Hemker, MD, Anthony Otley, MD, Marian Pfefferkorn, MD, Richard Kellermayer, MD, Scott Snapper, MD, Shervin Rabizadeh, MD, Ramnik Xavier, MD, PhD, Marla Dubinsky, MD, Jeffrey Hyams, MD, Subra Kugathasan, MD, Anil G Jegga, DVM, MS, Jonathan R Dillman, MD, MSc, Lee A Denson, MD
doi : 10.1093/ibd/izaa339
Inflammatory Bowel Diseases, Volume 27, Issue 11, November 2021, Pages 1707–1718
Transmural healing (TH) is associated with better long-term outcomes in Crohn disease (CD), whereas pretreatment ileal gene signatures encoding myeloid inflammatory responses and extracellular matrix production are associated with stricturing. We aimed to develop a predictive model for ileal TH and to identify ileal genes and microbes associated with baseline luminal narrowing (LN), a precursor to strictures.
Ultra-high Magnification Endocytoscopy and Molecular Markers for Defining Endoscopic and Histologic Remission in Ulcerative Colitis—An Exploratory Study to Define Deep Remission
Marietta Iacucci, PhD, Louisa Jeffery, PhD, Animesh Acharjee, PhD, Olga Maria Nardone, MD, Davide Zardo, MD, Samuel C L Smith, MRCP, Alina Bazarova, PhD, Rosanna Cannatelli, MD, Uday N Shivaji, MRCP, John Williams, PhD, Georgios Gkoutos, PhD, Subrata Ghosh, FCAHS
doi : 10.1093/ibd/izab059
Inflammatory Bowel Diseases, Volume 27, Issue 11, November 2021, Pages 1719–1730
Endoscopic and histological remission are both important treatment goals in patients with ulcerative colitis (UC). We aimed to define cellular architecture, expression of molecular markers, and their correlation with endoscopic scores assessed by ultra-high magnification endocytoscopy (ECS) and histological scores.
The Risk of Later Diagnosis of Inflammatory Bowel Disease in Patients With Dermatological Disorders Associated With Inflammatory Bowel Disease
Dominic King, MBChB, Joht Singh Chandan, PhD, Tom Thomas, MBBD, Krishnarajah Nirantharakumar, MD, Raoul C Reulen, PhD, Nicola J Adderley, PhD, Nigel Trudgill, MD
doi : 10.1093/ibd/izaa344
Inflammatory Bowel Diseases, Volume 27, Issue 11, November 2021, Pages 1731–1739
Dermatological conditions such as erythema nodosum (EN), pyoderma gangrenosum, Sweet’s syndrome, and aphthous stomatitis can occur with inflammatory bowel disease (IBD) and are considered dermatological extraintestinal manifestations (D-EIMs). Rarely, they may precede IBD. Other common conditions such as psoriasis have also been associated with IBD. This study examined the risk of a subsequent IBD diagnosis in patients presenting with a D-EIM.
Longitudinal Trajectory of Fatigue in Patients With Inflammatory Bowel Disease: A Prospective Study
Nienke Z Borren, MD, Millie D Long, MD, MPH, Robert S Sandler, MD, MPH, Ashwin N Ananthakrishnan, MD, MPH
doi : 10.1093/ibd/izaa338
Inflammatory Bowel Diseases, Volume 27, Issue 11, November 2021, Pages 1740–1746
Fatigue is a disabling symptom in patients with inflammatory bowel disease (IBD). Its prevalence, mechanism, and impact remain poorly understood. We determined changes in fatigue status over time and identified predictors of incident or resolving fatigue.
Ulcerative Colitis Narrative Global Survey Findings: The Impact of Living With Ulcerative Colitis—Patients’ and Physicians’ View
Marla C Dubinsky, MD, Kenji Watanabe, MD, Pauliina Molander, MD, Laurent Peyrin-Biroulet, MD, PhD, Michele Rubin, APN, Gil Y Melmed, MD, MS, J Jasper Deuring, PhD, John Woolcott, PhD, Joseph C Cappelleri, PhD, MPH, Kathy Steinberg, BSc, Susan Connor, MD, PhD on behalf of The Global UC Narrative Survey Panel
doi : 10.1093/ibd/izab016
Inflammatory Bowel Diseases, Volume 27, Issue 11, November 2021, Pages 1747–1755
The Ulcerative Colitis (UC) Narrative is a global patient and physician survey aimed at identifying the impact of UC and comparing and contrasting perceptions of UC burden and management approaches.
Randomized Controlled Trial: Perioperative Dexamethasone Reduces Excessive Postoperative Inflammatory Response and Ileus After Surgery for Inflammatory Bowel Disease
Tenghui Zhang, MD, Yi Xu, MD, Yao Yao, MD, Lingling Jin, MD, Haoxin Liu, MD, Yan Zhou, Lili Gu, PhD, Qing Ji, PhD, Weiming Zhu, PhD, Jianfeng Gong, PhD
doi : 10.1093/ibd/izab065
Inflammatory Bowel Diseases, Volume 27, Issue 11, November 2021, Pages 1756–1765
An excessive postoperative inflammatory response is common after surgery for inflammatory bowel disease (IBD) and may be associated with an increased incidence of postoperative ileus. This study assessed the role of perioperative dexamethasone in postoperative ileus after IBD surgery.
Fecal Microbiota Transplantation in Chronic Pouchitis: A Randomized, Parallel, Double-Blinded Clinical Trial
Essi K Karjalainen, MD, Laura Renkonen-Sinisalo, MD, PhD, Reetta Satokari, MSc, PhD, Harri Mustonen, DSc, Ari Ristimäki, MD, PhD, Perttu Arkkila, Anna H Lepistö, MD, PhD
doi : 10.1093/ibd/izab001
Inflammatory Bowel Diseases, Volume 27, Issue 11, November 2021, Pages 1766–1772
In ulcerative colitis, a pouchitis is the most common long-term adverse effect after proctocolectomy and ileal pouch-anal anastomosis. Approximately 5% of patients develop chronic antibiotic-dependent or antibiotic-refractory pouchitis without any effective treatment. The aim of this trial was to investigate the efficacy and safety of fecal microbiota transplantation in the treatment of chronic pouchitis.
Inflammatory Bowel Disease and Risk of Major Bleeding During Anticoagulation for Venous Thromboembolism
Susanna Scharrer, MD, Christian Primas, MD, Sabine Eichinger, MD, Sebastian Tonko, MD, Maximilian Kutschera, MS, Robert Koch, MD, Andreas Blesl, MD, Walter Reinisch, MD, Andreas Mayer, MD, Thomas Haas, MD, Thomas Feichtenschlager, MD, Harry Fuchssteiner, MD, Pius Steiner, MD, Othmar Ludwiczek, MD, Reingard Platzer, MD, Wolfgang Miehsler, MD, Wolfgang Tillinger, MD, Sigrid Apostol, MD, Alfons Schmid, MD, Karin Schweiger, MD, Harald Vogelsang, MD, Clemens Dejaco, MD, Harald Herkner, MD, Gottfried Novacek, MD Austrian IBD Study Group
doi : 10.1093/ibd/izaa337
Inflammatory Bowel Diseases, Volume 27, Issue 11, November 2021, Pages 1773–1783
Little is known about the bleeding risk in patients with inflammatory bowel disease (IBD) and venous thromboembolism (VTE) treated with anticoagulation. Our aim was to elucidate the rate of major bleeding (MB) events in a well-defined cohort of patients with IBD during anticoagulation after VTE.
Epidemiology of Inflammatory Bowel Diseases in Israel: A Nationwide Epi-Israeli IBD Research Nucleus Study
Mira Y Stulman, MPH, Noa Asayag, Gili Focht, MBA, Ilan Brufman, MSc, Amos Cahan, MD, Natan Ledderman, MD, Eran Matz, MD, Yehuda Chowers, MD, Rami Eliakim, MD, Shomron Ben-Horin, MD, Shmuel Odes, MD, Iris Dotan, MD, PhD, Ran D Balicer, MD, PhD, Eric I Benchimol, MD, PhD, Dan Turner, MD, PhD
doi : 10.1093/ibd/izaa341
Inflammatory Bowel Diseases, Volume 27, Issue 11, November 2021, Pages 1784–1794
There are currently no nationwide data on the epidemiology of inflammatory bowel diseases (IBD) in Israel. We aimed to determine the population-based epidemiological trends of IBD in the diverse Israeli population.
Occurrence of Colorectal Cancer and the Influence of Medical Treatment in Patients With Inflammatory Bowel Disease: A Danish Nationwide Cohort Study, 1997 to 2015
Petra Weimers, MD, Dorit Vedel Ankersen, MSc, Ellen Christine Leth Løkkegaard, PhD, Johan Burisch, PhD, Pia Munkholm, PhD
doi : 10.1093/ibd/izaa340
Inflammatory Bowel Diseases, Volume 27, Issue 11, November 2021, Pages 1795–1803
The risk of colorectal cancer (CRC) for patients with inflammatory bowel disease (IBD) has previously been investigated with conflicting results. We aimed to investigate the incidence and risk of CRC in IBD, focusing on its modification by treatment.
Unique Regulation of Coupled NaCl Absorption by Inducible Nitric Oxide in a Spontaneous SAMP1/YitFc Mouse Model of Chronic Intestinal Inflammation
Subha Arthur, PhD, Balasubramanian Palaniappan, PhD, Sheuli Afroz, PhD, Uma Sundaram, MD
doi : 10.1093/ibd/izab093
Inflammatory Bowel Diseases, Volume 27, Issue 11, November 2021, Pages 1804–1812
In the small intestine, Na:H (NHE3) and Cl:HCO3 (DRA or PAT1) exchangers present in the brush border membrane (BBM) of absorptive villus cells are primarily responsible for the coupled absorption of NaCl, the malabsorption of which causes diarrhea, a common symptom of inflammatory bowel disease (IBD). Inducible nitric oxide (iNO), a known mediator of inflammation, is increased in the mucosa of the chronically inflamed IBD intestine. An SAMP1/YitFc (SAMP1) mouse, a spontaneous model of chronic ileitis very similar to human IBD, was used to study alterations in NaCl absorption. The SAMP1 and control AKR mice were treated with I-N(6)-(1-Iminoethyl)-lysine (L-NIL) to inhibit iNO production, and DRA/PAT1 and NHE3 activities and protein expression were studied. Though Na:H exchange activity was unaffected, Cl:HCO3 activity was significantly decreased in SAMP1 mice due to a reduction in its affinity for Cl, which was reversed by L-NIL treatment. Though DRA and PAT1 expressions were unchanged in all experimental conditions, phosphorylation studies indicated that DRA, not PAT1, is affected in SAMP1. Moreover, the altered phosphorylation levels of DRA was restored by L-NIL treatment. Inducible NO mediates the inhibition of coupled NaCl absorption by decreasing Cl:HCO3 but not Na:H exchange. Specifically, Cl:HCO3 exchanger DRA but not PAT1 is regulated at the level of its phosphorylation by iNO in the chronically inflamed intestine.
Vedolizumab Tissue Concentration Correlates to Mucosal Inflammation and Objective Treatment Response in Inflammatory Bowel Disease
Renske W M Pauwels, MD, Elisa Proietti, MS, Christien J van der Woude, MD, PhD, Lindsey Oudijk, MD, Marie-Rose B S Crombag, PharmD, PhD, Maikel P Peppelenbosch, PhD, Ursula Grohmann, PhD, Gwenny M Fuhler, PhD, Annemarie C de Vries, MD, PhD
doi : 10.1093/ibd/izab053
Inflammatory Bowel Diseases, Volume 27, Issue 11, November 2021, Pages 1813–1820
The association between vedolizumab (VDZ) exposure and treatment response is unclear and seems insufficiently explained by serum levels. The aim of this study was to assess the correlation between VDZ concentrations in serum and intestinal tissue and their association with mucosal inflammation and response to VDZ.
HG-9-91-01 Attenuates Murine Experimental Colitis by Promoting Interleukin-10 Production in Colonic Macrophages Through the SIK/CRTC3 Pathway
Yong Fu, MS, Gailing Ma, BS, Yuqian Zhang, MS, Wenli Wang, MS, Tongguo Shi, PhD, Jie Zhu, PhD, Junfeng Zhang, PhD, Zhen Huang, PhD, Jiangning Chen, PhD
doi : 10.1093/ibd/izab072
Inflammatory Bowel Diseases, Volume 27, Issue 11, November 2021, Pages 1821–1831
Interleukin-10 (IL-10) is a potent immunoregulatory cytokine that plays a pivotal role in maintaining mucosal immune homeostasis. As a novel synthetic inhibitor of salt-inducible kinases (SIKs), HG-9-91-01 can effectively enhance IL-10 secretion at the cellular level, but its in vivo immunoregulatory effects remain unclear. In this study, we investigated the effects and underlying mechanism of HG-9-91-01 in murine colitis models.
Ocular Manifestations of Inflammatory Bowel Disease
Janaki Shah, MD, Aaditya Shah, MD, Lynn Hassman, MD, PhD, Alexandra Gutierrez, MD, MPH
doi : 10.1093/ibd/izaa359
Inflammatory Bowel Diseases, Volume 27, Issue 11, November 2021, Pages 1832–1838
Inflammatory bowel disease (IBD) is characterized by intestinal inflammation; however, it is also known to have extraintestinal manifestations. Ocular manifestations of IBD include keratopathy, episcleritis, scleritis, and uveitis and are among the most common extraintestinal manifestations. These diseases can lead to significant ocular morbidity if unrecognized and left untreated. A review of the literature was performed on PubMed and is summarized and critically appraised in this article with the aim being to describe the varying ocular manifestations of IBD and outlining their treatments. Ultimately, a framework is provided to investigate ocular symptoms in patients with IBD. An ocular review of systems is also provided as a tool to equip gastroenterologists and internal medicine physicians to be able to recognize and triage ocular complaints appropriately.
The Pathogenesis and Clinical Management of Stricturing Crohn Disease
Christopher J Schmoyer, MD, MS, Jakob Saidman, MD, Jaime L Bohl, MD, Claire L Bierly, John F Kuemmerle, MD, Stephen J Bickston, MD, AGAF, FACG, FASGE
doi : 10.1093/ibd/izab038
Inflammatory Bowel Diseases, Volume 27, Issue 11, November 2021, Pages 1839–1852
Stricturing of the gastrointestinal tract is a common complication in Crohn disease and is a significant cause of morbidity and mortality among this population. The inflammatory process initiates fibrosis, leading to aberrant wound healing and excess deposition of extracellular matrix proteins. Our understanding of this process has grown and encompasses cellular mechanisms, epigenetic modifications, and inherent genetic predisposition toward fibrosis. Although medications can improve inflammation, there is still no drug to attenuate scar formation. As such, management of stricturing disease requires a multidisciplinary and individualized approach including medical management, therapeutic endoscopy, and surgery. This review details the current understanding regarding the pathogenesis, detection, and management of stricturing Crohn disease.
Mevalonate Kinase Deficiency: A Cause of Severe Very-Early-Onset Inflammatory Bowel Disease
Brigitte Bader-Meunier, MD, Andreia Luís Martins, MD, Fabienne Charbit-Henrion, MD, PhD, Ulrich Meinzer, MD, PhD, Alexandre Belot, MD, PhD, Laurence Cuisset, PhD, Albert Faye, MD, PhD, Sophie Georgin-Lavialle, MD, PhD, Pierre Quartier, MD, Vanessa Remy-Piccolo, MD, Frank Ruemmele, MD, PhD, Florence Uettwiller, MD, Jérôme Viala, MD, PhD, Nadine Cerf Bensussan, MD, PhD, Dominique Berrebi, MD, PhD, Isabelle Melki, MD, PhD
doi : 10.1093/ibd/izab139
Inflammatory Bowel Diseases, Volume 27, Issue 11, November 2021, Pages 1853–1857
Mevalonate kinase deficiency should be considered in patients with severe very-early-onset inflammatory bowel disease (IBD), especially in patients with a history of recurrent or chronic fever, peritoneal adhesions, and atypical IBD pathology. Anti-interleukin-1 therapy may be efficacious in these patients with monogenic very-early-onset IBD.
SARS-CoV-2 Vaccination in Patients With Inflammatory Bowel Disease—Fear and Desire
Jens Walldorf, MD, Ulrike von Arnim, MD, Renate Schmelz, MD, Anica Riesner-Wehner, MD, Patrick Michl, MD, Philip C Grunert, MC, Andreas Stallmach, MD, Niels Teich, MD, Philipp A Reuken, MD
doi : 10.1093/ibd/izab150
Inflammatory Bowel Diseases, Volume 27, Issue 11, November 2021, Pages 1858–1861
Seroconversion Following SARS-CoV-2 Infection or Vaccination in Pediatric IBD Patients
Elizabeth A Spencer, MD, Eyal Klang, MD, Michael Dolinger, MD, MBA, Nanci Pittman, MD, Marla C Dubinsky, MD
doi : 10.1093/ibd/izab194
Inflammatory Bowel Diseases, Volume 27, Issue 11, November 2021, Pages 1862–1864
Very-Early-Onset Inflammatory Bowel Disease in a Patient With Junctional Epidermolysis Bullosa With a Homozygous Mutation in the ?6 Integrin Gene (ITGA6)
Hassan Vahidnezhad, PhD, Leila Youssefian, PhD, Mohammad Hossein Anbardar, MD, Sirous Zeinali, PhD, Rahele A Farahani, MD, Jouni Uitto, MD, PhD
doi : 10.1093/ibd/izab141
Inflammatory Bowel Diseases, Volume 27, Issue 11, November 2021, Pages 1865–1869
Expanding Contributions of Monogenic Very Early Onset Inflammatory Bowel Disease
Jodie Ouahed, MD, MMSc
doi : 10.1093/ibd/izab145
Inflammatory Bowel Diseases, Volume 27, Issue 11, November 2021, Pages 1870–1872
Currently over 70 genes known to be causative in very early onset inflammatory bowel disease (VEOIBD) have been identified. In the current issue of Inflammatory Bowel Diseases, 2 articles describing monogenetic forms of VEOIBD are highlighted. One describes a patient with life-threatening VEOIBD and a mutation in ITGA6, illustrating the importance of the epithelial barrier in maintaining mucosal homeostasis. The other describes the presentation and management of 10 patients with VEOIBD secondary to damaging mutations in MVK, resulting in mevalonate kinase deficiency. Though most monogenic causes of VEOIBD remain “private,” understanding the different categories of pathways affected in children with VEOIBD is critical and has already resulted in invaluable insight in the management of patients with VEOIBD and may hold strong implications for the care of IBD overall.
Fecal Microbiota Transplantation for Chronic Pouchitis: Promising Novel Therapeutic or Lost Cause?
Rahul S Dalal, MD, Jessica R Allegretti, MD, MPH
doi : 10.1093/ibd/izab002
Inflammatory Bowel Diseases, Volume 27, Issue 11, November 2021, Pages 1873–1875
Predictors: How to Approach the Individualization of Treatment
Daniel Ceballos, MD, PhD
doi : 10.1093/ibd/izaa228
Inflammatory Bowel Diseases, Volume 27, Issue 11, November 2021, Pages 1876–1877
The “big data” in inflammatory bowel disease opens a route of detection of predictors that can determine the prognosis of each patient and allow the individualized selection of more efficient and safe therapeutic strategies. Immune biomarkers are a promising field to explore thoroughly.
Call for Emergency Action to Limit Global Temperature Increases, Restore Biodiversity, and Protect Health: Wealthy nations must do much more, much faster1
Lukoye Atwoli, Abdullah H Baqui, Thomas Benfield, Raffaella Bosurgi, Fiona Godlee, Stephen Hancocks, Richard Horton, Laurie Laybourn-Langton, Carlos Augusto Monteiro, Ian Norman, Kirsten Patrick, Nigel Praities, Marcel G M Olde Rikkert, Eric J Rubin, Peush Sahni, Richard Smith, Nick Talley, Sue Turale, Damián Vázquez
doi : 10.1093/ibd/izab225
Inflammatory Bowel Diseases, Volume 27, Issue 11, November 2021, Pages 1878–1880
An Unusual Cause of Chest Pain With Abdominal Pain
Xiaolei Liu, MD, Yongquan Shi, MD, Min Chen, MD
doi : 10.1093/ibd/izab127
Inflammatory Bowel Diseases, Volume 27, Issue 11, November 2021, Pages e130–e131
Vedolizumab-Induced Endoscopic and Histologic Improvement in Gastric Menetrier’s Disease in a Patient With Ulcerative Colitis
Anas Hussameddin, MD, Rocio Sedano, MD, Darryl Ramsewak, MD, David Driman, MBChB, Vipul Jairath, MD, PhD
doi : 10.1093/ibd/izab129
Inflammatory Bowel Diseases, Volume 27, Issue 11, November 2021, Pages e132–e133
Acceptance of SARS-CoV-2 Vaccination Among a Cohort of IBD Patients From Southern Italy: A Cross-Sectional Survey
Federica Crispino, MD, Daniele Brinch, MD, Lucio Carrozza, MD, Maria Cappello, MD
doi : 10.1093/ibd/izab133
Inflammatory Bowel Diseases, Volume 27, Issue 11, November 2021, Pages e134–e135
Self-Expandable Metal Stents for Refractory Complete Rectal Obstruction in Patients With Crohn Disease
Antonietta Lamazza, MD, Enrico Fiori, MD, Maria Vittoria Carati, MD, Anna Maria Pronio, MD, Angelo Antoniozzi, MD, Antonio V Sterpetti, MD
doi : 10.1093/ibd/izab137
Inflammatory Bowel Diseases, Volume 27, Issue 11, November 2021, Pages e136–e137
Appendiceal Orifice Inflammation in Severe Ulcerative Colitis and Its Resolution With Infliximab and Plant-based Diet as First-line Therapy
Mitsuro Chiba, MD, PhD, Hajime Ishii, MD, PhD, Masato Sageshima, MD, PhD, Akira Iwabuchi, MD, PhD
doi : 10.1093/ibd/izab168
Inflammatory Bowel Diseases, Volume 27, Issue 11, November 2021, Pages e138–e139
The ACE (Albumin, CRP, and Endoscopy) Index in Acute Colitis: Simplify to a Better Prognostic Prediction
Ana Luísa Santos, MD, Susana Lopes, MD, PhD, Armando Peixoto, MD, Isabel Garrido, PhD, Renato Medas, Patrícia Andrade, Guilherme Macedo, MD, PhD
doi : 10.1093/ibd/izab189
Inflammatory Bowel Diseases, Volume 27, Issue 11, November 2021, Page e140
Low Serum Tumor Necrosis Factor-? Antagonist Concentrations in Patients With Inflammatory Bowel Disease Who Achieve Healing From Pyoderma Gangrenosum
Maria Mikail, MB, BCh, Aze Wilson, MD, PhD
doi : 10.1093/ibd/izab148
Inflammatory Bowel Diseases, Volume 27, Issue 11, November 2021, Pages e141–e143
